Despite the strong results, investigators cautioned that the study has limitations, including its open-label Phase II design, lack of randomization, and reliance on a historical external control arm
Baxfendy works in a fundamentally different way from current therapies
Access to genomic testing, not therapy cost, is the biggest challenge
Nationwide preventive health initiative aims to make cardiovascular screening at age 30 a standard healthcare milestone
Africa CDC activates continental coordination measures; consultations underway on possible Public Health Emergency declaration
High-resolution analytical platforms from Agilent Technologies will be made available through C-CAMP’s shared infrastructure model under expanded collaboration
Lormalzi is the first and only once-monthly amyloid plaque-targeting therapy with clinical evidence
The two companies will establish a joint Center of Excellence (CoE) in Bengaluru
The six-part webinar series aims to enhance awareness, diagnosis, and management of autoimmune diseases
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
